

Jeffery P Struewing

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4716728/publications.pdf>

Version: 2024-02-01

100
papers

29,265
citations

44069

48
h-index

32842

100
g-index

102
all docs

102
docs citations

102
times ranked

40070
citing authors

#	ARTICLE	IF	CITATIONS
1	The Genotype-Tissue Expression (GTEx) project. <i>Nature Genetics</i> , 2013, 45, 580-585.	21.4	6,815
2	The Genotype-Tissue Expression (GTEx) pilot analysis: Multitissue gene regulation in humans. <i>Science</i> , 2015, 348, 648-660.	12.6	4,659
3	Genetic Heterogeneity and Penetrance Analysis of the BRCA1 and BRCA2 Genes in Breast Cancer Families. <i>American Journal of Human Genetics</i> , 1998, 62, 676-689.	6.2	2,662
4	Genome-wide association study identifies novel breast cancer susceptibility loci. <i>Nature</i> , 2007, 447, 1087-1093.	27.8	2,165
5	The Risk of Cancer Associated with Specific Mutations of <i>BRCA1</i> and <i>BRCA2</i> among Ashkenazi Jews. <i>New England Journal of Medicine</i> , 1997, 336, 1401-1408.	27.0	2,135
6	Germline p16 mutations in familial melanoma. <i>Nature Genetics</i> , 1994, 8, 15-21.	21.4	1,170
7	Multifactorial Analysis of Differences Between Sporadic Breast Cancers and Cancers Involving BRCA1 and BRCA2 Mutations. <i>Journal of the National Cancer Institute</i> , 1998, 90, 1138-1145.	6.3	652
8	The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals. <i>Nature Genetics</i> , 1995, 11, 198-200.	21.4	625
9	The eMERGE Network: A consortium of biorepositories linked to electronic medical records data for conducting genomic studies. <i>BMC Medical Genomics</i> , 2011, 4, 13.	1.5	618
10	Increased Risk of Pancreatic Cancer in Melanoma-Prone Kindreds with p16 ^{INK4} Mutations. <i>New England Journal of Medicine</i> , 1995, 333, 970-975.	27.0	608
11	A common coding variant in CASP8 is associated with breast cancer risk. <i>Nature Genetics</i> , 2007, 39, 352-358.	21.4	591
12	The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%. <i>Nature Genetics</i> , 1996, 14, 188-190.	21.4	375
13	Parity, Oral Contraceptives, and the Risk of Ovarian Cancer among Carriers and Noncarriers of a <i>BRCA1</i> or <i>BRCA2</i> Mutation. <i>New England Journal of Medicine</i> , 2001, 345, 235-240.	27.0	370
14	Population-based study of risk of breast cancer in carriers of BRCA2 mutation. <i>Lancet</i> , The, 1998, 352, 1337-1339.	13.7	325
15	Heterogeneity of Breast Cancer Associations with Five Susceptibility Loci by Clinical and Pathological Characteristics. <i>PLoS Genetics</i> , 2008, 4, e1000054.	3.5	315
16	Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families. <i>Nature Medicine</i> , 1996, 2, 1179-1183.	30.7	294
17	Effect of predicted protein-truncating genetic variants on the human transcriptome. <i>Science</i> , 2015, 348, 666-669.	12.6	252
18	RAD51 135G ⁺ C Modifies Breast Cancer Risk among BRCA2 Mutation Carriers: Results from a Combined Analysis of 19 Studies. <i>American Journal of Human Genetics</i> , 2007, 81, 1186-1200.	6.2	217

#	ARTICLE	IF	CITATIONS
19	The Prevalence of Common BRCA1 and BRCA2 Mutations among Ashkenazi Jews. <i>American Journal of Human Genetics</i> , 1999, 64, 963-970.	6.2	204
20	Antibody to Capsular Polysaccharides of <i>Streptococcus pneumoniae</i> : Prevalence, Persistence, and Response to Revaccination. <i>Clinical Infectious Diseases</i> , 1993, 17, 66-73.	5.8	176
21	The APC I1307K allele and cancer risk in a community-based study of Ashkenazi Jews. <i>Nature Genetics</i> , 1998, 20, 62-65.	21.4	176
22	Effect of <i>BRCA</i> Mutations on the Length of Survival in Epithelial Ovarian Tumors. <i>Journal of Clinical Oncology</i> , 2002, 20, 463-466.	1.6	175
23	Genotype-Phenotype Relationships in U.S. Melanoma-Prone Families With <i>CDKN2A</i> and <i>CDK4</i> Mutations. <i>Journal of the National Cancer Institute</i> , 2000, 92, 1006-1010.	6.3	172
24	Polymorphisms in DNA double-strand break repair genes and risk of breast cancer: two population-based studies in USA and Poland, and meta-analyses. <i>Human Genetics</i> , 2006, 119, 376-388.	3.8	144
25	Prophylactic Oophorectomy Reduces Breast Cancer Penetrance During Prospective, Long-Term Follow-Up of <i>BRCA1</i> Mutation Carriers. <i>Journal of Clinical Oncology</i> , 2005, 23, 8629-8635.	1.6	138
26	A natural history of melanomas and dysplastic nevi. <i>Cancer</i> , 2002, 94, 3192-3209.	4.1	137
27	The Kin-Cohort Study for Estimating Penetrance. <i>American Journal of Epidemiology</i> , 1998, 148, 623-630.	3.4	134
28	SJS/TEN 2017: Building Multidisciplinary Networks to Drive Science and Translation. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2018, 6, 38-69.	3.8	134
29	Psychosocial factors predicting <i>BRCA1/BRCA2</i> testing decisions in members of hereditary breast and ovarian cancer families. <i>American Journal of Medical Genetics Part A</i> , 2000, 93, 257-263.	2.4	124
30	<i>FGFR2</i> variants and breast cancer risk: fine-scale mapping using African American studies and analysis of chromatin conformation. <i>Human Molecular Genetics</i> , 2009, 18, 1692-1703.	2.9	110
31	The risk of measles, mumps, and varicella among young adults: a serosurvey of US Navy and Marine Corps recruits.. <i>American Journal of Public Health</i> , 1993, 83, 1717-1720.	2.7	101
32	Gynecologic Surgeries and Risk of Ovarian Cancer in Women With <i>BRCA1</i> and <i>BRCA2</i> Ashkenazi Founder Mutations: An Israeli Population-Based Case-Control Study. <i>Journal of the National Cancer Institute</i> , 2003, 95, 1072-1078.	6.3	96
33	Association of <i>ESR1</i> gene tagging SNPs with breast cancer risk. <i>Human Molecular Genetics</i> , 2009, 18, 1131-1139.	2.9	84
34	A twofold increase in <i>BRCA</i> mutation related prostate cancer among Ashkenazi Israelis is not associated with distinctive histopathology. <i>Journal of Medical Genetics</i> , 2003, 40, 787-792.	3.2	82
35	Performance of high-throughput DNA quantification methods. <i>BMC Biotechnology</i> , 2003, 3, 20.	3.3	81
36	A Single Genetic Origin for the G101W <i>CDKN2A</i> Mutation in 20 Melanoma-Prone Families. <i>American Journal of Human Genetics</i> , 2000, 67, 311-319.	6.2	80

#	ARTICLE	IF	CITATIONS
37	Survival After Breast Cancer in Ashkenazi Jewish BRCA1 and BRCA2 Mutation Carriers. <i>Journal of the National Cancer Institute</i> , 1999, 91, 259-263.	6.3	75
38	Kin-cohort estimates for familial breast cancer risk in relation to variants in DNA base excision repair, BRCA1 interacting and growth factor genes. <i>BMC Cancer</i> , 2004, 4, 9.	2.6	73
39	Prospective risk of cancer in CDKN2A germline mutation carriers. <i>Journal of Medical Genetics</i> , 2004, 41, 421-424.	3.2	69
40	XPD gene polymorphism and host characteristics in the association with cutaneous malignant melanoma risk. <i>British Journal of Cancer</i> , 2004, 90, 497-502.	6.4	68
41	Fine scale mapping of the breast cancer 16q12 locus. <i>Human Molecular Genetics</i> , 2010, 19, 2507-2515.	2.9	68
42	Construction of a transcription map surrounding the BRCA1 locus of human chromosome 17. <i>Genomics</i> , 1995, 25, 238-247.	2.9	62
43	Population attributes affecting the prevalence of BRCA mutation carriers in epithelial ovarian cancer cases in israel. <i>Gynecologic Oncology</i> , 2003, 89, 494-498.	1.4	61
44	Polymorphisms in DNA repair genes, ionizing radiation exposure and risk of breast cancer in U.S. Radiologic technologists. <i>International Journal of Cancer</i> , 2008, 122, 177-182.	5.1	58
45	The ATM missense mutation p.Ser49Cys (c.146C>G) and the risk of breast cancer. <i>Human Mutation</i> , 2006, 27, 538-544.	2.5	56
46	Genetic epidemiology of epithelial ovarian cancer. <i>Cancer</i> , 1993, 71, 566-572.	4.1	56
47	Potential Excess Mortality in BRCA1/2 Mutation Carriers beyond Breast, Ovarian, Prostate, and Pancreatic Cancers, and Melanoma. <i>PLoS ONE</i> , 2009, 4, e4812.	2.5	53
48	Hyperendemic <i>Streptococcus pyogenes</i> Infection despite Prophylaxis with Penicillin G Benzathine. <i>New England Journal of Medicine</i> , 1991, 325, 92-97.	27.0	52
49	Founder BRCA1/2 Mutations among Male Patients with Breast Cancer in Israel. <i>American Journal of Human Genetics</i> , 1999, 65, 1800-1802.	6.2	50
50	Mutational analysis of the BRCA1-interacting genes ZNF350/ZBRK1 and BRIP1/BACH1 among BRCA1 and BRCA2-negative probands from breast-ovarian cancer families and among early-onset breast cancer cases and reference individuals. <i>Human Mutation</i> , 2003, 22, 121-128.	2.5	49
51	Candidate Single Nucleotide Polymorphism Selection using Publicly Available Tools: A Guide for Epidemiologists. <i>American Journal of Epidemiology</i> , 2006, 164, 794-804.	3.4	49
52	Prevalence of <i>Toxoplasma gondii</i> Antibodies in U.S. Military Recruits in 1989: Comparison with Data Published in 1965. <i>Clinical Infectious Diseases</i> , 1996, 23, 1182-1183.	5.8	47
53	Histopathologic Features of Ovaries at Increased Risk for Carcinoma. <i>International Journal of Gynecological Pathology</i> , 1999, 18, 151-157.	1.4	47
54	Polymorphisms in Apoptosis- and Proliferation-Related Genes, Ionizing Radiation Exposure, and Risk of Breast Cancer among U.S. Radiologic Technologists. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2007, 16, 2000-2007.	2.5	45

#	ARTICLE	IF	CITATIONS
55	Sonographic studies of schoolchildren in a village endemic for <i>Schistosoma mansoni</i> . <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 1990, 84, 69-73.	1.8	41
56	DNA damage among thyroid cancer and multiple cancer cases, controls, and long-lived individuals. <i>Mutation Research - Genetic Toxicology and Environmental Mutagenesis</i> , 2005, 586, 173-188.	1.7	41
57	<i>BRCA1/2</i> testing in hereditary breast and ovarian cancer families: Effectiveness of problem-solving training as a counseling intervention. <i>American Journal of Medical Genetics Part A</i> , 2004, 130A, 221-227.	2.4	40
58	<i>BRCA1</i> mutations in young women with breast cancer. <i>Lancet, The</i> , 1996, 347, 1493.	13.7	39
59	Efficiency of DNA pooling to estimate joint allele frequencies and measure linkage disequilibrium. <i>Genetic Epidemiology</i> , 2002, 22, 94-102.	1.3	39
60	Thyroid Nodules, Polymorphic Variants in DNA Repair and <i>RET</i> -Related Genes, and Interaction with Ionizing Radiation Exposure from Nuclear Tests in Kazakhstan. <i>Radiation Research</i> , 2009, 171, 77-88.	1.5	38
61	<i>BRCA1/2</i> testing in hereditary breast and ovarian cancer families II: Impact on relationships. <i>American Journal of Medical Genetics, Part A</i> , 2005, 133A, 165-169.	1.2	36
62	Breast Cancer Risk in Ashkenazi <i>BRCA1/2</i> Mutation Carriers: Effects of Reproductive History. <i>Epidemiology</i> , 2002, 13, 255-261.	2.7	35
63	Frequency of <i>BRCA</i> Mutations in Primary Peritoneal Carcinoma in Israeli Jewish Women. <i>Gynecologic Oncology</i> , 2003, 88, 58-61.	1.4	35
64	HapScope: a software system for automated and visual analysis of functionally annotated haplotypes. <i>Nucleic Acids Research</i> , 2002, 30, 5213-5221.	14.5	34
65	Heterogeneity of risk for melanoma and pancreatic and digestive malignancies. <i>Cancer</i> , 2004, 101, 2809-2816.	4.1	33
66	Breast Cancer Risk Polymorphisms and Interaction with Ionizing Radiation among U.S. Radiologic Technologists. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2008, 17, 2007-2011.	2.5	32
67	Analysis of genetic variation in Ashkenazi Jews by high density SNP genotyping. <i>BMC Genetics</i> , 2008, 9, 14.	2.7	31
68	<i>AURKA</i> F31I Polymorphism and Breast Cancer Risk in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers: A Consortium of Investigators of Modifiers of <i>BRCA1/2</i> Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2007, 16, 1416-1421.	2.5	30
69	AN EPIDEMIC OF RESPIRATORY COMPLAINTS EXACERBATED BY MASS PSYCHOGENIC ILLNESS IN A MILITARY RECRUIT POPULATION. <i>American Journal of Epidemiology</i> , 1990, 132, 1120-1129.	3.4	29
70	<i>CDKN2A</i> point mutations D153spl(c.457G>T) and IVS2+1G>T result in aberrant splice products affecting both p16 ^{INK4a} and p14 ^{ARF} . <i>Oncogene</i> , 2003, 22, 4444-4448.	5.9	29
71	A common founder for the V126D <i>CDKN2A</i> mutation in seven North American melanoma-prone families. <i>British Journal of Cancer</i> , 2001, 85, 527-530.	6.4	28
72	Papillary Thyroid Cancer and Polymorphic Variants in <i>TSHR</i> - and <i>RET</i> -Related Genes: a Nested Case-Control Study within a Cohort of U.S. Radiologic Technologists. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2007, 16, 174-177.	2.5	28

#	ARTICLE	IF	CITATIONS
73	The HER2 I655V Polymorphism and Breast Cancer Risk in Ashkenazim. <i>Epidemiology</i> , 2003, 14, 694-700.	2.7	27
74	<i>BRCA1/2</i> testing in hereditary breast and ovarian cancer families III: Risk perception and screening. <i>American Journal of Medical Genetics, Part A</i> , 2006, 140A, 2198-2206.	1.2	26
75	The AIB1 Polyglutamine Repeat Does Not Modify Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2006, 15, 76-79.	2.5	26
76	No evidence of excess breast cancer risk among mutation-negative women from BRCA mutation-positive families. <i>Breast Cancer Research and Treatment</i> , 2011, 125, 169-173.	2.5	26
77	Systematic analysis of genetic alterations in tumors using Cancer Genome WorkBench (CGWB). <i>Genome Research</i> , 2007, 17, 1111-1117.	5.5	24
78	CHEK2:1100delC and female breast cancer in the United States. <i>International Journal of Cancer</i> , 2004, 112, 541-543.	5.1	20
79	Similar prevalence of founder BRCA1 and BRCA2 mutations among Ashkenazi and non-Ashkenazi men with breast cancer: Evidence from 261 cases in Israel, 1976-1999. <i>European Journal of Medical Genetics</i> , 2008, 51, 141-147.	1.3	20
80	Localisation of the breast-ovarian cancer susceptibility gene (BRCA1) on 17q12-21 to an interval of 1cM. <i>Genes Chromosomes and Cancer</i> , 1994, 10, 71-76.	2.8	18
81	Patients with Double Primary Tumors in the Breast and Ovary: Clinical Characteristics and BRCA1-2 Mutations Status. <i>Gynecologic Oncology</i> , 2000, 79, 74-78.	1.4	18
82	Polymorphisms in estrogen biosynthesis and metabolism-related genes, ionizing radiation exposure, and risk of breast cancer among US radiologic technologists. <i>Breast Cancer Research and Treatment</i> , 2009, 118, 177-184.	2.5	18
83	Efficacy of Hepatitis B Vaccination in Primary School Children from a Village Endemic for <i>Schistosoma mansoni</i> . <i>Journal of Infectious Diseases</i> , 1992, 166, 265-268.	4.0	17
84	Interpreting a single antistreptolysin o test: A comparison of the upper limit of normal and likelihood ratio methods. <i>Journal of Clinical Epidemiology</i> , 1993, 46, 1181-1185.	5.0	17
85	Localization of breast cancer susceptibility loci by genome-wide SNP linkage disequilibrium mapping. <i>Genetic Epidemiology</i> , 2006, 30, 48-61.	1.3	17
86	Adverse drug reaction causality assessment tools for drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: room for improvement. <i>European Journal of Clinical Pharmacology</i> , 2019, 75, 1135-1141.	1.9	16
87	Oral Erythromycin Prophylaxis against <i>Streptococcus pyogenes</i> Infection in Penicillin-Allergic Military Recruits: A Randomized Clinical Trial. <i>Journal of Infectious Diseases</i> , 1992, 166, 162-165.	4.0	15
88	Skewed X chromosome inactivation and early-onset breast cancer. <i>Journal of Medical Genetics</i> , 2005, 43, 48-53.	3.2	15
89	Automated Detection of Prevalent Mutations in <i>BRCA1</i> and <i>BRCA2</i> Genes, Using a Fluorogenic PCR Allelic Discrimination Assay. <i>Genetic Testing and Molecular Biomarkers</i> , 1997, 1, 171-180.	1.7	14
90	Quantitation of DNA in buccal cell samples collected in epidemiological studies. <i>Biomarkers</i> , 2006, 11, 472-479.	1.9	14

#	ARTICLE	IF	CITATIONS
91	Meeting Research Needs with Postmortem Biospecimen Donation: Summary of Recommendations for Postmortem Recovery of Normal Human Biospecimens for Research. <i>Biopreservation and Biobanking</i> , 2013, 11, 77-82.	1.0	13
92	Re: Population-Based, Case-Control Study of HER2 Genetic Polymorphism and Breast Cancer Risk. <i>Journal of the National Cancer Institute</i> , 2003, 95, 1251-1252.	6.3	9
93	The BRCA1 Ashkenazi founder mutations occur on common haplotypes and are not highly correlated with anonymous single nucleotide polymorphisms likely to be used in genome-wide case-control association studies. <i>BMC Genetics</i> , 2007, 8, 68.	2.7	8
94	BRCA1 and sex ratio. <i>European Journal of Human Genetics</i> , 2004, 12, 663-667.	2.8	7
95	BRCA1 in Special Populations. <i>Breast Disease</i> , 1998, 10, 71-75.	0.8	6
96	Re: Effect of BRCA1 and BRCA2 on the Association Between Breast Cancer Risk and Family History. <i>Journal of the National Cancer Institute</i> , 1999, 91, 1250-1251.	6.3	5
97	Genomic Approaches to Identifying Breast Cancer Susceptibility Factors. <i>Breast Disease</i> , 2004, 19, 3-9.	0.8	5
98	Allelic Loss on Chromosome 8p in BRCA-1 Mutation Positive Breast/Ovarian Cancers. <i>Breast Journal</i> , 1998, 4, 9-12.	1.0	4
99	Tuberculosis infection among young adults entering the US Navy in 1990. <i>Archives of Internal Medicine</i> , 1993, 153, 211-216.	3.8	3
100	Melanoma-prone kindreds with p16 mutation are also at risk of pancreatic cancer. <i>Advances in Anatomic Pathology</i> , 1996, 3, 250.	4.3	0